20 Dec, EOD - Indian

SENSEX 78041.59 (-1.49)

Nifty 50 23587.5 (-1.52)

Nifty Bank 50759.2 (-1.58)

Nifty IT 43771.05 (-2.63)

Nifty Midcap 100 56906.75 (-2.82)

Nifty Next 50 68702.65 (-2.72)

Nifty Pharma 22501.85 (-0.86)

Nifty Smallcap 100 18714.3 (-2.19)

20 Dec, EOD - Global

NIKKEI 225 38701.9 (-0.29)

HANG SENG 19720.7 (-0.16)

S&P 6008.5 (1.05)

Login/Signup
LOGIN HERE
Cancel

Divis Laboratories Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 532488 | NSE Symbol : DIVISLAB | ISIN : INE361B01024 | Industry : Pharmaceuticals |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
29-Oct-2024 09-Nov-2024 Quarterly Results DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2024 inter alia to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter and half year ended September 30 2024. Submission of financial results for the quarter and half year ended September 30, 2024. (As Per BSE Announcement Dated on 09.11.2024)
25-Jul-2024 03-Aug-2024 Quarterly Results DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2024 inter alia to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended June 30 2024. As per enclosed letter. Further to our intimation dated July 25, 2024, we would like to inform that the Board of Directors of the Company at its meeting held on August 03, 2024 has approved the unaudited financial results for the quarter ended June 30, 2024. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following: 1. Statement of standalone unaudited financial results for the quarter ended June 30, 2024 and Limited Review Report of the Statutory Auditors thereon. 2. Statement of consolidated unaudited financial results for the quarter ended June 30, 2024 and Limited Review Report of the Statutory Auditors thereon. 3. Press release on the financial results of the Company. Read less.. (As Per BSE Announcement Dated on 03.08.2024)
15-May-2024 25-May-2024 Dividend DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2024 inter alia to consider and approve Audited financial results for the quarter and year ended March 31 2024 and recommend dividend fi any on the equity shares of the Company for the financial year 2023-24. As per enclosed letter. (As Per BSE Announcement Dated on 25.05.2024)
30-Jan-2024 10-Feb-2024 Quarterly Results DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2024 inter alia to consider and approve the standalone and consolidated unaudited financial results for the quarter and nine months ended December 31 2023 As per enclsoed attachment. (As Per BSE Announcement Dated on 10.02.2024)
26-Oct-2023 06-Nov-2023 Quarterly Results DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2023 inter alia to consider and approve standalone and consolidated unaudited financial results for the quarter and half year ended September 30 2023. As per enclsoed. (As Per BSE Announcement Dated on 06.11.2023)
05-Aug-2023 14-Aug-2023 Quarterly Results DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2023 inter alia to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30 2023. As enclosed (As Per BSE Announcement Dated on 14.08.2023)
12-May-2023 20-May-2023 Accounts DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2023 inter alia to consider and approve 1. Audited standalone and consolidated financial results of the Company for the fourth quarter and year ended March 31 2023; and 2. Final dividend if any on equity shares of the Company for the financial year ended March 31 2023. As enclsoed Recommended a Dividend of ? 30/- (i.e. 1,500%) per equity share of face value ? 2/- each for the financial year 2022-23, subject to approval of the members at the ensuing 33rd Annual General Meeting (AGM). The dividend shall be credited / warrants thereof dispatched within specified timelines from the conclusion of the AGM. The AGM date and record date for the purpose of the payment of dividend will be announced in due course. (As Per BSE Announcement Dated on 20/05/2023)
23-Jan-2023 03-Feb-2023 Quarterly Results DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 inter alia to consider and approve the standalone and consolidated unaudited financial results for the quarter and nine months ended December 31 2022. Further to our intimation dated January 23, 2023, we would like to inform that the Board of Directors of the Company at its meeting held on February 03, 2023 has, inter alia approved the unaudited financial results for the quarter and nine months ended December 31, 2022. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose herewith the following: 1. Unaudited standalone financial results for the quarter and nine months ended December 31, 2022 along with Limited Review Report of the Statutory Auditors thereon. 2. Unaudited consolidated financial results for quarter and nine months ended December 31, 2022 along with Limited Review Report of the Statutory Auditors thereon. 3. Press Release on the said financial results of the Company. (As per BSE Announcement Dated on 03/02/2023)
28-Oct-2022 07-Nov-2022 Quarterly Results DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2022 inter alia to consider and approve the standalone and consolidated unaudited financial results for the quarter and half year ended September 30 2022. As intimated earlier the Trading Window for dealing in securities of the Company has been closed from October 01 2022 till 48 hours after the declaration of financial results as per the Companys Code of Conduct for Prevention of Insider Trading pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015. Further to our intimation dated October 28, 2022, we would like to inform that the Board of Directors of the Company at its meeting held on November 07, 2022 has, inter alia, approved the Unaudited Financial Results for the quarter and half year ended September 30, 2022. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose herewith the following: 1. Unaudited standalone financial results for the quarter and half year ended September 30, 2022 along with Limited Review Report of the Statutory Auditors thereon. 2. Unaudited consolidated financial results for quarter and half year ended September 30, 2022 along with Limited Review Report of the Statutory Auditors thereon. 3. Press Release on the said Financial Results of the Company. The Board meeting commenced at 11.30 Hrs and concluded at 12.40 Hrs. (As Per BSE Announcement Dated on 07.11.2022)
28-Jul-2022 12-Aug-2022 Quarterly Results DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2022 inter alia to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30 2022. Further to our intimation dated July 28, 2022, we would like to inform that the Board of Directors of the Company at its meeting held on Friday, August 12, 2022 has approved the Unaudited Financial Results for the quarter ended June 30, 2022. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following: 1. Statement of Standalone Unaudited Financial Results for the quarter ended June 30, 2022 and Limited Review Report of the Statutory Auditors thereon. 2. Statement of Consolidated Unaudited Financial Results for the quarter ended June 30, 2022 and Limited Review Report of the Statutory Auditors thereon. 3. Press Release on the Financial Results of the Company. The Board meeting commenced at 11.00 Hrs and concluded at 12.15 Hrs (As per BSE Announcement Dated on 12/08/2022)
13-May-2022 23-May-2022 Dividend Dividend & Audited Results DIVI''s LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2022 ,inter alia, to consider and approve audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2022 and to recommend dividend, if any, on equity shares of the Company for the financial year 2021-22. As intimated earlier, the Trading Window for dealing in securities of the Company has been closed from April 01, 2022 till 48 hours after the declaration of financial results as per the Code of Conduct of the Company pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015. Divis Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 23, 2022, inter alia, has recommended a Dividend of Rs. 30/- (i.e. 1500%) per equity share of face value Rs. 2/- each for the financial year 2021-22, subject to approval of the members at the ensuing 32nd Annual General Meeting (AGM). The dividend shall be credited/ warrants thereof dispatched within 30 (thirty) days from the conclusion of the AGM. As per enclosed (As Per BSE Announcement Dated on 23.05.2022)
25-Jan-2022 11-Feb-2022 Quarterly Results DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2022 inter alia to consider and approve Notice is hereby given that a meeting of Board of Directors of the Company is scheduled to be held on Friday February 04 2022 inter-alia to consider and approve the standalone and consolidated unaudited financial results for the quarter and nine months ended December 31 2021. As informed earlier pursuant to the Code of Conduct for Prevention of Insider Trading of the Company the Trading Window for dealing in securities of the Company has been closed for Designated Persons and their Immediate Relatives as well as Insiders covered under the Code from January 01 2022 till 48 hours after the declaration of Unaudited Financial Results for the quarter and nine months ended December 31 2021. (As Per BSE Announcement Dated on 29/01/2022) Quarterly Results (Revised) (As per BSE Bulletin Dated on 01/02/20222) The Board Meeting to be held on 04/02/2022 has been revised to 11/02/2022 The Board Meeting to be held on 04/02/2022 has been revised to 11/02/2022 (As Per BSE Announcement dated on 01.02.2022) Further to our intimation dated February 01, 2022, we would like to inform that the Board of Directors of the Company at its meeting held on February 11, 2022 has, inter alia approved the Unaudited Financial Results for the quarter and nine months ended December 31, 2021. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose herewith the following: 1. Unaudited standalone financial results for the quarter and nine months ended December 31, 2021 along with Limited Review Report of the Statutory Auditors thereon. 2. Unaudited consolidated financial results for quarter and nine months ended December 31, 2021 along with Limited Review Report of the Statutory Auditors thereon. 3. Press Release on the said Financial Results of the Company. The Board meeting commenced at 10.30 Hrs and concluded at 11.50 Hrs Outcome of Board Meeting held on 11.02.2022 - re-appointment of directors (As Per BSE Announcement dated on 11.02.2022)
28-Oct-2021 06-Nov-2021 Quarterly Results Quarterly Results Further to our intimation dated October 28, 2021, we would like to inform that the Board of Directors of the Company at its meeting held on November 06, 2021 has, inter alia, approved the Unaudited Financial Results for the quarter and half year ended September 30, 2021. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose herewith the following: 1. Unaudited standalone financial results for the quarter and half year ended September 30, 2021 along with Limited Review Report of the Statutory Auditors thereon. 2. Unaudited consolidated financial results for quarter and half year ended September 30, 2021 along with Limited Review Report of the Statutory Auditors thereon. 3. Press Release on the said Financial Results of the Company. The Board meeting commenced at 10.00 Hrs and concluded at 11.40 Hrs. Further to our intimation dated October 28, 2021, we would like to inform that the Board of Directors of the Company at its meeting held on November 06, 2021 has, inter alia, approved the Unaudited Financial Results for the quarter and half year ended September 30, 2021. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose herewith the following: 1. Unaudited standalone financial results for the quarter and half year ended September 30, 2021 along with Limited Review Report of the Statutory Auditors thereon. 2. Unaudited consolidated financial results for quarter and half year ended September 30, 2021 along with Limited Review Report of the Statutory Auditors thereon. 3. Press Release on the said Financial Results of the Company. The Board meeting commenced at 10.00 Hrs and concluded at 11.40 Hrs. (As Per BSE Announcement Dated on 06.11.2021)
30-Jul-2021 07-Aug-2021 Quarterly Results DIVI''s LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2021 ,inter alia, to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2021. As intimated earlier, the Trading Window for dealing in securities of the Company has been closed from July 01, 2021 till 48 hours after the declaration of financial results as per the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015. As enclosed. (As Per BSE Announcement Dated on 07.08.2021)
21-May-2021 29-May-2021 Accounts DIVI''s LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2021 ,inter alia, to consider and approve Notice is hereby given that a meeting of Board of Directors of the Company is scheduled to be held on Saturday, 29 May, 2021, inter-alia, to consider and approve standalone and consolidated audited financial results for the quarter and year ended 31 March, 2021 and to recommend dividend, if any, on equity shares for the financial year 2020-21. As intimated earlier, the Trading Window for dealing in securities of the Company has been closed from 01 April, 2021 till 48 hours after the declaration of financial results as per the Code of Conduct of the Company pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015. This is for your information and records. As Per enclosed. As per attachment(As Per BSE Announcement Dated on 5/29/2021)
1 2